Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -73.82% and Operating profit at -232.08% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -3.51
2
Negative results in Jun 25
3
Risky - Negative EBITDA
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 50 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.24
89.25%
-5.46
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-33.48%
0%
-33.48%
6 Months
-30.0%
0%
-30.0%
1 Year
-17.42%
0%
-17.42%
2 Years
-45.76%
0%
-45.76%
3 Years
-85.31%
0%
-85.31%
4 Years
-85.02%
0%
-85.02%
5 Years
0%
0%
0.0%
Spectral AI, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-73.82%
EBIT Growth (5y)
-232.08%
EBIT to Interest (avg)
-3.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.59
Sales to Capital Employed (avg)
-1.70
Tax Ratio
3.60%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.89%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-31.67
EV to EBIT
-8.56
EV to EBITDA
-9.34
EV to Capital Employed
-6.12
EV to Sales
1.52
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 4 Schemes (3.46%)
Foreign Institutions
Held by 10 Foreign Institutions (3.17%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
5.10
6.70
-23.88%
Operating Profit (PBDIT) excl Other Income
-2.00
-0.80
-150.00%
Interest
0.10
0.60
-83.33%
Exceptional Items
-5.40
4.50
-220.00%
Consolidate Net Profit
-8.00
2.90
-375.86%
Operating Profit Margin (Excl OI)
-419.20%
-133.60%
-28.56%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -23.88% vs -11.84% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -375.86% vs 137.66% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
29.60
18.10
63.54%
Operating Profit (PBDIT) excl Other Income
-6.00
-12.30
51.22%
Interest
3.00
0.00
Exceptional Items
-5.50
-8.00
31.25%
Consolidate Net Profit
-15.30
-20.90
26.79%
Operating Profit Margin (Excl OI)
-222.50%
-719.10%
49.66%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 63.54% vs -28.74% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 26.79% vs -620.69% in Dec 2023
About Spectral AI, Inc. 
Spectral AI, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






